Visual hallucinations and illusions in Parkinson's disease: the role of ocular pathology.


Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 09 04 2020
accepted: 14 05 2020
revised: 12 05 2020
pubmed: 25 5 2020
medline: 21 5 2021
entrez: 25 5 2020
Statut: ppublish

Résumé

Whether different mechanisms, particularly ocular pathology, could lead to the emergence of visual hallucinations (VH) (defined as false perceptions with no external stimulus) versus visual illusions (VI) (defined as a misperception of a real stimulus) in Parkinson's disease (PD) remains debated. We assessed retinal, clinical and structural brain characteristics depending on the presence of VH or VI in PD. In this case-control study, we compared retinal thickness using optical coherence tomography (OCT), between PD patients with: VI (PD-I; n = 26), VH (PD-H; n = 28), and without VI or VH (PD-C; n = 28), and assessed demographic data, disease severity, treatment, anatomical and functional visual complaints, cognitive and visuo-perceptive functions and MRI brain volumetry for each group of PD patients. Parafoveal retina was thinner in PD-H compared to PD-C (p = 0.005) and PD-I (p = 0.009) but did not differ between PD-I and PD-C (p = 0.85). Multivariate analysis showed that 1/retinal parafoveal thinning and total brain gray matter atrophy were independently associated with the presence of VH compared to PD-I; 2/retinal parafoveal thickness, PD duration, sleep quality impairment and total brain gray matter volume were independent factors associated with the presence of VH compared to PD-C; 3/anterior ocular abnormalities were the only factor independently associated with the presence of illusions compared to PD-C. These findings reinforce the hypothesis that there may be different mechanisms contributing to VH and VI in PD, suggesting that these two entities may also have a different prognosis rather than simply lying along a continuous spectrum. Clinicaltrials.gov number NCT01114321.

Identifiants

pubmed: 32447550
doi: 10.1007/s00415-020-09925-x
pii: 10.1007/s00415-020-09925-x
doi:

Banques de données

ClinicalTrials.gov
['NCT01114321']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2829-2841

Subventions

Organisme : Fondation de France
ID : 76354

Auteurs

Ana Marques (A)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France. ar_marques@chu-clermontferrand.fr.

Steven Beze (S)

Ophtalmology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Bruno Pereira (B)

Biostatistics Department, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Carine Chassain (C)

Imaging Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Nathalie Monneyron (N)

Ophtalmology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Laure Delaby (L)

CMRR, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Celine Lambert (C)

Ophtalmology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Marie Fontaine (M)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Philippe Derost (P)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Bérengère Debilly (B)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Isabelle Rieu (I)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Simon J G Lewis (SJG)

Brain and Mind Center, Parkinson's Disease Research Clinic, University of Sydney, Sydney, Australia.

Frédéric Chiambaretta (F)

Ophtalmology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Franck Durif (F)

Neurology Department, Université Clermont-Auvergne, EA7280, Clermont-Ferrand University Hospital, Clermont-Ferrand, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH